HART adds to board as it moves toward new human trials
Courtesy Youtube
Harvard Apparatus Regenerative Technology of Holliston has named a biotechnology executive to its board.
Blaine McKee, Ph.D., senior vice president and head of transactions at Shire plc, has been named to the board. He will also serve on the board’s audit committee, bringing HART back into compliance with the Nasdaq Capital Market's requirement for audit committee composition.
According to a release from HART, McKee is a broadly skilled senior executive with over 20 years of leadership experience in global biotechnology business development. He was previously EVP and Chief Business Officer at 480 Biomedical, following 15 years at Sanofi-Genzyme, where he served as SVP of Strategic Development. At Sanofi, he led global business development for the organ transplant, oncology and multiple sclerosis business units.
With an extensive background in science, finance and strategy, Dr. McKee will help guide HART's development activities including its current focus on completing an Investigative New Drug application to the U.S. Food and Drug Administration. The goal of the application is to initiate human clinical trials for HART's newly developed Cellframe technology for organ implants, according to the company.
WBJ Web Partners
Most Recent
Most Recent
0 Comments